MET and hepatocellular carcinoma: The cytotoxicity against many HCC cell lines of tivantinib was unrelated to c-Met expression but related to inhibiting microtubule assembly (Aoyama et al., 2014) and Glycogen Synthase Kinase-3 alpha (GSK3a) and beta (GSK3b) (Remsing Rix et al., 2014) in other studies.